MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

Taxane therapy remains the standard of care for triple-negative breast cancer. However, high frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer cells can acquire resistance to this drug. The actin regulatory protein MENA and particularly its invasive...

Full description

Bibliographic Details
Main Authors: Han, Sangyoon (Author), Jonas, Oliver (Author), Oudin, Madeleine Julie (Contributor), Barbier, Lucie (Contributor), Schafer, Claudia (Contributor), Kosciuk, Tatsiana (Contributor), Miller, Miles Aaron (Contributor), Lauffenburger, Douglas A (Contributor), Gertler, Frank (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Association for Cancer Research (AACR), 2018-06-19T18:24:08Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items